{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":20,"description":"All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks","id":"EG000","otherNumAffected":17,"otherNumAtRisk":20,"seriousNumAffected":2,"seriousNumAtRisk":20,"title":"Pasireotide LAR"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":20}],"term":"Abdominal distension"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":20}],"term":"Abdominal pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":20}],"term":"Diarrhoea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":20}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":20}],"term":"Blood glucose increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":20}],"term":"Diabetes mellitus"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":20}],"term":"Dyslipidaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":20}],"term":"Hyperglycaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":20}],"term":"Type 2 diabetes mellitus"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":20}],"term":"Arthralgia"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20}],"term":"Cholelithiasis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20}],"term":"Hand fracture"}],"timeFrame":"Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to approximately 104 weeks"}